PAVmed Inc.
PAVMHealthcareNASDAQMedical Devices · Last scanned Oct 24, 2026
Scan Results
Daily timeframePAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. At a $17.4M market cap, PAVmed Inc. ranks as a micro-cap company within healthcare. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device.
Market Cap
$17.4M
Beta
0.70
P/E (TTM)
—
P/E (Fwd)
-0.91
EPS (TTM)
$-15.45
EPS (Fwd)
$-2.38
ROE
-64.8%
ROA
-39.7%
Cash
$4.1M
Total Debt
$17.1M
Free CF
-$11.9M
52W Change
-82.3%
Annual Financials
Cash vs Debt
Where PAVM stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PAVM finished 62.25% below its 150-day moving average ($5.96) and 67.01% below its 200-day moving average ($6.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PAVM overbought or oversold?
At the October 20, 2026 close, PAVM's RSI(14) was 19.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $4.1M in cash, though total debt stands at $17.1M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$11.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -64.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $377K to $71K.
With a beta below 0.7, PAVmed Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence PAVmed Inc.'s trajectory.